Company news

BioCardia, Inc. news in 2025

BioCardia, Inc.'s news releases, calls and decks from 2025, newest first.

View company

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

December 16, 2025

BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

December 3, 2025

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

December 1, 2025

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

November 24, 2025

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

November 12, 2025

BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial

November 10, 2025

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

November 5, 2025

BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial

October 30, 2025

BioCardia Regains Compliance with Nasdaq Listing Requirements

October 2, 2025

BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

September 22, 2025

BioCardia Announces Pricing of Up To $12 Million Public Offering

September 18, 2025

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

September 18, 2025

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

September 4, 2025

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology

August 13, 2025

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

August 11, 2025

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

August 6, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

August 4, 2025

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure

July 24, 2025

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

July 15, 2025

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

June 25, 2025

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 14, 2025

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

May 9, 2025

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

May 6, 2025

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

May 1, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

April 15, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

April 11, 2025

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4: 30PM EDT Time Today

March 31, 2025

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

March 31, 2025

BioCardia Reports 2024 Business Highlights and Financial Results

March 26, 2025

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

March 21, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

March 10, 2025

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

February 27, 2025

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

February 12, 2025

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

January 26, 2025

Calls in 2025

Decks in 2025